2008-05-14 23:52:59 -
www.avantimmune.com - AVANT Immunotherapeutics, Inc. Anthony S. Marucci, 781-433-0771 President and CEO or Avery W. Catlin, 781-433-0771 Chief Financial Officer info@avantimmune.com or For Media: BMC Communications Group Daniel Budwick, 212-477-9007 dbudwick@bmccommunications.com AVANT Immunotherapeutics, Inc. (Nasdaq: AVAN) will release its first quarter 2008 financial results before U.S. financial markets open on Monday, May 19, 2008.
AVANT executives will host a
conference call and live audio webcast at 10:00 am ET that same day. To access the live call, dial 888-713-4214 (within the United States) or 617-213-4866 (outside the United States). The passcode for participants is 94627424. A replay will be available approximately two hours after the live call. To access the replay, dial 888-286-8010 (within the United States) or 617-801-6888 (outside the United States). The passcode I.D. # is 25264226. The replay will also be broadcast via the company's website www.avantimmune.com approximately two hours after the live call.
About AVANT Immunotherapeutics, Inc.
AVANT Immunotherapeutics, Inc. is a NASDAQ-listed company discovering and developing innovative vaccines and targeted immunotherapeutics for the treatment of cancer, infectious and inflammatory diseases. AVANT focuses on the use of tumor-specific targets and human monoclonal antibodies (mAbs) to precisely deliver therapeutic agents through its novel "targeted immunization" approach. In addition, AVANT is also exploiting its access to proprietary human antibody technology for development of therapeutics monoclonal antibodies (mAbs). AVANT's deep product pipeline consists of products in varying stages of development, with its lead candidate, CDX-110, currently undergoing evaluation in a Phase 2/3 clinical trial in newly diagnosed glioblastoma multiforme, one of the most aggressive forms of brain cancer. AVANT also has several product candidates in its development pipeline including:
-- CDX-1307, a product based on its proprietary APC Targeting Technology(TM), which is in two Phase 1 clinical trials for patients with advanced pancreatic, bladder, breast and colon cancer;
-- TP10, a complement inhibitor, in development for transplantation and other indications; and
-- Three candidates based on its oral, rapidly-protecting, single-dose and temperature-stable vaccine technology, including combination vaccines for travelers, the military and global health needs.
AVANT has three commercialized products, including Rotarix(R) (partnered with GSK) for the prevention of rotavirus infection and two human food safety vaccines for reducing salmonella infection in chickens and eggs.
Conference Call to Follow
